Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 11/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | THPO | P40225 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.56 |
| ▸ | GRM5 | P41594 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | FBP1 | P09467 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300301 | 0.93 | NFE2L2 (0.71) | NFE2L2CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL18240554 | 0.88 | NFE2L2 (0.69) | NFE2L2CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL18240610 | 0.83 | NFE2L2 (0.54) | NFE2L2CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL18240598 | 0.83 | NFE2L2 (0.72) | NFE2L2CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL700304 | 0.81 | NFE2L2 (1.00) | NFE2L2CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL14401249 | 0.81 | NFE2L2 (1.00) | NFE2L2CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL700305 | 0.81 | NFE2L2 (1.00) | NFE2L2CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL29446272 | 0.81 | NFE2L2 (1.00) | NFE2L2CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL18240697 | 0.80 | ACHE (0.64) | NFE2L2CYP1A2CYP3A4CYP2D6PKM | |
| SCHEMBL18240567 | 0.80 | NFE2L2 (0.56) | NFE2L2CYP1A2CYP3A4CYP2D6PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | claimed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | claimed |
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | disclosed |
| US-8299072-B2 | Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-30 | — | — | US | disclosed |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-04-15 | — | — | US | disclosed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | disclosed |
| EP-1361225-B1 | COMPOUNDS SUBSTITUTED WITH BICYCLIC AMINO GROUPS | SANKYO CO (JP) | 2007-11-07 | — | — | EP | disclosed |
| CN-1294129-C | Heteraryl-substituted porrole derivatives, their prep. and therapeutic use | SANKYO CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-7091352-B2 | Compounds substituted with bicyclic amino groups | SANKYO COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| US-6030975-A | ANTAGONIST OF ENDOTHELINS, I.E. INHIBITION OF BINDING WITH RECEPTOR; ANTITUMOR AND -CARCINOGENIC AGENTS; SIDE EFFECT REDUCTION | BASF AKTIENGESELLSCHAFT (DE) | 2000-02-29 | — | — | US | disclosed |
| US-5840722-A | ADMINISTERING TO INHIBIT ENDOTHELIN RECEPTORS | BASF AKTIENGESELLSCHAFT (DE) | 1998-11-24 | — | — | US | disclosed |
| US-5840684-A | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| US-5792840-A | SUBSTITUTED GLUCOPYRANOSYL PHOSPHATES | SANKYO COMPANY, LIMITED (JP) | 1998-08-11 | — | — | US | disclosed |
| US-5661106-A | HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-08-26 | — | — | US | disclosed |
| EP-0437016-B1 | Lipid A analogues having immunoactivating and anti-tumour activity | SANKYO CO (JP) | 1996-05-01 | — | — | EP | disclosed |
| EP-0695296-A1 | 3-(HETERO)ARYLOXY(THIO) CARBOXYLIC ACID DERIVATIVES, METHOD OF PREPARING THEM AND INTERMEDIATES USED IN THEIR PREPARATION | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-07 | — | — | EP | disclosed |
| WO-1994025443-A1 | 3-(HETERO)ARYLOXY(THIO) CARBOXYLIC ACID DERIVATIVES, METHOD OF PREPARING THEM AND INTERMEDIATES USED IN THEIR PREPARATION | BASF AKTIENGESELLSCHAFT (DE) | 1994-11-10 | — | — | WO | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | NFE2L2 387/4885CYP1A2 665/4885CYP3A4 2846/4885 |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1B, CACNA1C, ORAI1 | NFE2L2 3063/4885CYP1A2 3803/4885CYP3A4 2679/4885 |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1I, CACNA1C, ORAI1 | NFE2L2 3204/4885CYP1A2 2881/4885CYP3A4 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.